311 related articles for article (PubMed ID: 12222989)
1. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Kherani RB; Papaioannou A; Adachi JD
Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
4. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
5. Etidronate and alendronate in the treatment of postmenopausal osteoporosis.
Beauchesne MF; Miller PF
Ann Pharmacother; 1999 May; 33(5):587-99. PubMed ID: 10369624
[TBL] [Abstract][Full Text] [Related]
6. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Giljević Z; Vlak T
Reumatizam; 2006; 53(2):66-71. PubMed ID: 17580558
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian JP
Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
[TBL] [Abstract][Full Text] [Related]
9. Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W; Emkey R; Civitelli R
Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
[TBL] [Abstract][Full Text] [Related]
10. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
11. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Ringe JD; Möller G
Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
[TBL] [Abstract][Full Text] [Related]
12. [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
Curković B
Reumatizam; 2003; 50(2):49-50. PubMed ID: 15098377
[TBL] [Abstract][Full Text] [Related]
13. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates for the treatment of postmenopausal osteoporosis: clinical studies of etidronate and alendronate.
Harris ST
Osteoporos Int; 2001 Dec; 12 Suppl 3():S11-6. PubMed ID: 11846336
[TBL] [Abstract][Full Text] [Related]
15. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD; Delmas PD
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
[TBL] [Abstract][Full Text] [Related]
16. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
[TBL] [Abstract][Full Text] [Related]
17. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
18. A comparison of continuous alendronate, cyclical alendronate and cyclical etidronate with calcitriol in the treatment of postmenopausal vertebral osteoporosis: a randomized controlled trial.
Sahota O; Fowler I; Blackwell PJ; Lawson N; Cawte SA; San P; Masud T; Hosking DJ
Osteoporos Int; 2000; 11(11):959-66. PubMed ID: 11193249
[TBL] [Abstract][Full Text] [Related]
19. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Dunn CJ; Goa KL
Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
[TBL] [Abstract][Full Text] [Related]
20. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]